Results 141 to 150 of about 16,087 (221)

Bayesian Workflow for Minimal PBPK Models: Case Study of Dapagliflozin

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Numerous clinical trials (CTs) and population pharmacokinetic (PK) models have been published on dapagliflozin, an approved SGLT2 inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. This study proposes a Bayesian workflow for the development of minimal physiologically‐based PK models (mPBPK) that integrates all ...
Anna Mikhailova, Kirill Peskov, Gabriel Helmlinger, Victor Sokolov   +3 more
wiley   +1 more source

Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study). [PDF]

ESC Heart Fail
Leszek P, Csanádi Z, Gruev I, Uuetoa T, Žaliaduonytė D, Miličić D, Trušinskis K, Baukienė J, Isvoranu AM, Chioncel O.   +9 more
europepmc   +1 more source

Peri‐operative management of diabetes mellitus: a multidisciplinary consensus statement from the Association of Anaesthetists and the Joint British Diabetes Societies for Inpatient Care group

Anaesthesia, Volume 81, Issue 8, Page 1116-1131, August 2026.
Summary Introduction Surgery in patients with diabetes mellitus is associated with increased morbidity and mortality compared with those who do not have diabetes mellitus. This is likely multifactorial and could be attributed to organisational issues; dysglycaemia; hospital‐acquired diabetic ketoacidosis; errors with insulin prescribing and ...
Nicholas A. Levy, Kariem El‐Boghdadly, Dileep N. Lobo, Daniel J. Stubbs, Parizad Avari, Donal Buggy, Claire Frank, Kim Howson, Jinty Moffett, Emma Morris, Omar G. Mustafa, Glynn Nash, Pádraig Ó Scanaill, Sarah Procter, Gerry Rayman, Kim Russon, Caroline Thomas, Sarah Tinsley, Allan Xu, Ketan Dhatariya   +19 more
wiley   +1 more source

Targeting epicardial adipose tissue in heart failure with preserved ejection fraction: exploring the dapagliflozin connection. [PDF]

BMC Cardiovasc Disord
Soliman AM, Ghaleb R, Mahmoud AH, Heidar MAA, Ibrahim A.   +4 more
europepmc   +1 more source

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Pulmonary hypertension (PH) is a complex disorder associated with significant morbidity and mortality. PH is characterized by an elevated pulmonary vascular load, leading to right ventricular dysfunction and remodeling, with right heart failure and premature death if left untreated.
Surya Ayalasomayajula, Ednan K. Bajwa, Alexandra G. Cornell, Maria Jose Loureiro, Samuel S. Kim, Julia Richmond DiBello, Eric Sterner, Richard Chen, Islam R. Younis   +8 more
wiley   +1 more source

The effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit in diabetic kidney disease. [PDF]

Rev Assoc Med Bras (1992)
Karaköse S, Doğan B, Ergül F, Güney İ.   +3 more
europepmc   +1 more source

The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7083-7093, August 2026.
ABSTRACT Introduction Pharmacokinetic data suggest a potential dose‐dependent effect of sodium–glucose co‐transporter‐2 (SGLT‐2) inhibitors on surrogate markers of efficacy, but the impact of SGLT‐2 inhibitor dose on renal and cardiovascular outcomes remains uncertain.
Elias John Elenjickal, Frédéric Baroz, Philippe Boileau, Michael A. Tsoukas, Abhinav Sharma, Thomas A. Mavrakanas   +5 more
wiley   +1 more source

Dapagliflozin ameliorates motor deficits in a Parkinson's disease model induced by 6-OHDA: An integrative in vivo and in silico approach from α-synuclein/A2AAR/TH/TNF-α to APAF-1/caspase-3 modulation. [PDF]

Inflammopharmacology
Sezen S, Burul F, Okkay U, Karadayı M, Ozkaraca M, Bayram C, Gülşahin Y, Ferah Okkay I, Gulluce M.   +8 more
europepmc   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6874-6887, August 2026.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh, Brandon Michael Henry, István Édes   +2 more
wiley   +1 more source

Dapagliflozin attenuates cisplatin-induced nephrotoxicity in rats through modulation of ROS/NF-κB, BCL2/Bax and PINK1/Parkin signaling pathways. [PDF]

Sci Rep
Khallaf EK, Ramadan EA, Elmazar MM, Safar MM.   +3 more
europepmc   +1 more source